Press Releases

RSS feed

Partnership for a gene therapy Clinical trial signed between Genethon and Children’s Hospital Boston

A unique multicenter international study of gene therapy for a rare genetic disease (Wiskott-Aldrich syndrome) led in London, Paris and Boston. Genethon, the not-for-profit biotherapy laboratory funded by the French Muscular Dystrophy Association (AFM) thanks to the donations collected during the French Telethon, and Children’s Hospital Boston announce that they have initiated a partnership to conduct a gene therapy … [Read more]

bluebird bio and Généthon Announce Manufacturing Research Collaboration Centered on Lentiviral Vectors for Gene Therapy

Cambridge, Mass. And Evry, France, December 14, 2010 – bluebird bio (formerly Genetix Pharmaceuticals Inc.), an emerging leader in the development of innovative gene therapies for severe genetic disorders, and Généthon, a leader in the field of gene therapy treatments for rare diseases, today announced a research collaboration focused on process development and scale up efforts for the manufacturing of … [Read more]

Thérapie génique – la découverte d’un mini-gène fonctionnel ouvre une nouvelle voie thérapeutique dans les dysferlinopathies

Read the press release [FR]

Innovative biotherapies and genetic eye diseases

Innovative biotherapies and genetic eye diseases: the Réseau Thérapie Génique Oculaire (Ocular Gene Therapy Network) prepares to launch human trials Tomorrow, around thirty innovative biotherapy and genetic eye disease experts* will gather together at Généthon (Evry) to review, for the first time, the studies carried out so far as part of the Réseau Thérapie Génique … [Read more]

Généthon initiates a new clinical trial for a severe immune deficiency (Wiskott-Aldrich syndrome)

Généthon, the not-for-profit biotherapy laboratory operated by the French Muscular Dystrophy Association (AFM) with funding from the country’s annual Telethon*, has just obtained approval from the French and British health authorities for a Phase I/II clinical trial of gene therapy for a rare immunodeficiency, Wiskott-Aldrich syndrome (WAS). Read the press release (pdf, 2 p, 44 … [Read more]

Genethon appoints biopharma industry expert Frédéric Revah as Chief Executive

Genethon, the not-for-profit biotherapy research centre created by the French Muscular Dystrophy Association (AFM) and funded with donations from the country’s annual Telethon, today announced the appointment of Frédéric Revah PhD as Chief Executive. Frédéric Revah brings over 20 years’ experience in the pharmaceutical and biotech industries and academic research to the job. Genethon will … [Read more]

Journée internationale Maladies Rares du 28 février 2010 : Les acteurs de la Plateforme Maladies Rares attendent un second plan français à la hauteur de enjeux

Read the press release – 18/02/10 (1 page – 39 ko) [FR]

An effective gene therapy approach for dysferlin deficiencies

Research scientists at Généthon find a solution to the problem of the dysferlin gene’s size to transport it into muscle A team of researchers led by Isabelle Richard (CNRS UMR8587 LAMBE) in the Généthon laboratory, created and funded by AFM through Téléthon, has just demonstrated the efficacy in animals of a gene therapy strategy for … [Read more]

Thermo Fischer Scientific 2009 prize

Anne Galy, winner of the Biotherapy prize for her project “gene therapy in Wiskott-Aldrich syndrome” On 22 June, at the 8th annual conference of the “Société Francophone de Thérapie Cellulaire et Génique” (French-speaking Cellular and Gene Therapy Society) in Paris, Anne Galy, Généthon research director of the Inserm unit, will be presented the 2009 Biotherapy … [Read more]

Gene therapy: Production of the first batch of HIV-derived vectors in Europe for use in a human clinical trial

Genethon, the laboratory created and funded by the AFM (French Association against Myopathies) using donations from Téléthon, today announced that it has produced, controlled and released a batch of lentiviral vectors derived from the human immunodeficiency (HIV) virus for a gene therapy trial in humans in a rare immune deficiency. The Etablissement de thérapie génique … [Read more]